#### (19) World Intellectual Property Organization International Bureau





## (43) International Publication Date 25 May 2001 (25.05.2001)

#### PCT

# (10) International Publication Number WO 01/36005 A3

(51) International Patent Classification7: A61K 47/48, 49/00, 41/00

(21) International Application Number: PCT/US00/31424

(22) International Filing Date:

15 November 2000 (15.11.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/165,563

15 November 1999 (15.11.1999)

- (71) Applicant: UNIVERSITY OF SOUTHERN CALI-FORNIA [US/US]; 3716 South Hope Street, Suite 313, Los Angeles, CA 90007-4344 (US).
- (72) Inventors: PRESS, Michael: USC/Norris Comprehensive Cancer Center and Hospital, University of Southern California, 1441 Eastlake Avenue, Los Angeles, CA 90033 (US). PARK, Jinha; 1218 Pine Street, #303, South Pasadena, CA 91030 (US).
- (74) Agent: YADAV, Rajiv; McCutchen, Doyle, Brown & Enersen, LLP, Three Embarcadero Center, San Francisco, CA 94111 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

with international search report

(88) Date of publication of the international search report: 24 January 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

#### (54) Title: TARGETED DELIVERY OF THERAPEUTIC AND DIAGNOSTIC MOIETIES

(57) Abstract: Compositions and methods for improving cellular internalization of one or more compounds are disclosed. The invention provides a drug conjugate composition that can be delivered to a target cell, which comprises a carrier compound that has a binding specificity for a receptor molecule and is conjugated to a therapeutic or diagnostic moiety. When this composition is administered to a subject, the carrier compound binds to the receptor and is internalized by the target cell. Furthermore, monoclonal antibodies are disclosed that are internalized into target cells. The monoclonal antibodies of the invention are specific for target cells, particularly for cells expressing the surface antigen p185HER-2. The antibodies of the invention may be conjugated with a molecule for delivery into a target cell. Such molecules may be used for therapeutic treatment, including gene therapy, and for imaging. The invention also provides DNA sequences of the variable regions of particular monoclonal antibodies.

Interna. al Application No PCT/US 00/31424

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K47/48 A61K49/00

A61K41/00

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, EMBASE, BIOSIS, EPO-Internal

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO 01 00244 A (GENENTECH INC ;SCHWALL RALPH (US); ERICKSON SHARON (US)) 4 January 2001 (2001-01-04) claims	1-66
X	PARDRIDGE, WILLIAM M. ET AL: "Enhanced endocytosis in cultured human breast carcinoma cells and in vivo biodistribution in rats of a humanized monoclonal antibody after cationization of the protein"  J. PHARMACOL. EXP. THER. (1998), 286(1), 548-554, XP001024036 abstract page 549, column 2, paragraph 4 page 550, column 2, paragraph 5; figures 3,5,7	1-60

X Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
<ul> <li>Special categories of cited documents:</li> <li>A* document defining the general state of the art which is not considered to be of particular relevance</li> <li>E* earlier document but published on or after the international filling date</li> <li>L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</li> <li>O* document referring to an oral disclosure, use, exhibition or other means</li> <li>P* document published prior to the international filling date but later than the priority date claimed</li> </ul>	<ul> <li>'T' later document published after the international filing date or pnority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</li> <li>'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</li> <li>'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</li> <li>'&amp;' document member of the same patent family</li> </ul>
Date of the actual completion of the international search	Date of mailing of the international search report
20 September 2001	24/10/2001
Name and mailing address of the ISA  European Patent Office, P.B. 5818 Patentlaan 2  NL – 2280 HV Rijswijk  Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,	Authorized officer
Fax: (+31-70) 340-2040, 1x. 31 651 epo 111,	Berte, M

5

Interna al Application No
PCT/US 00/31424

	PCT/US 00/31424
ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
SCHMIDT, MATHIAS ET AL: "Synergistic Interaction between an Anti-p185HER-2 Pseudomonas Exotoxin Fusion Protein 'scFv(FRP5)-ETA! and Ionizing Radiation for Inhibiting Growth of Ovarian Cancer Cells That Overexpress HER-2" GYNECOL. ONCOL. (2001), 80(2), 145-155, XP001024046 abstract; figure 6	1-3,8-66
XU, FENGJI ET AL: "Synergistic interaction between anti-p185HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2" CLIN. CANCER RES. (2000), 6(8), 3334-3341  XP001024035 abstract; table 2	1-3,8-66
PARK, J. W. ET AL: "Development of anti-p185HER2 immunoliposomes for cancer therapy" PROC. NATL. ACAD. SCI. U. S. A. (1995), 92(5), 1327-31, XP002177492	1-3, 10-15, 21-23, 25-28, 30-33, 35-37, 43,53
abstract 	
XING, RUYE ET AL: "Control of breast tumor cell growth using a targeted cysteine protease inhibitor" CANCER RES. (1998), 58(5), 904-909, XP002177494 abstract page 904, column 2, paragraph 5 page 906, column 2, paragraph 3; figures 3-5 page 908, column 1, paragraph 3	1-66
WO 01 21192 A (CORIXA CORP ;CHEEVER MARTIN A (US); GAIGER ALEXANDER (US)) 29 March 2001 (2001-03-29) page 1, paragraph 3; claims page 20, paragraph 3 - paragraph 4	1-66
WO 93 17715 A (IMP CANCER RES TECH ;UNIV TEXAS (US)) 16 September 1993 (1993-09-16) claims 1,32,33	1-66
	SCHMIDT, MATHIAS ET AL: "Synergistic Interaction between an Anti-pl85HER-2 Pseudomonas Exotoxin Fusion Protein 'scFv(FRP5)-ETA! and Ionizing Radiation for Inhibiting Growth of Ovarian Cancer Cells That Overexpress HER-2" GYNECOL. ONCOL. (2001), 80(2), 145-155, XP001024046 abstract; figure 6  XU, FENGJI ET AL: "Synergistic interaction between anti-pl85HER-2 ricin A chain immunotoxins and radionuclide conjugates for inhibiting growth of ovarian and breast cancer cells that overexpress HER-2" CLIN. CANCER RES. (2000), 6(8), 3334-3341, XP001024035 abstract; table 2  PARK, J. W. ET AL: "Development of anti-pl85HER2 immunoliposomes for cancer therapy" PROC. NATL. ACAD. SCI. U. S. A. (1995), 92(5), 1327-31, XP002177492 abstract  XING, RUYE ET AL: "Control of breast tumor cell growth using a targeted cysteine protease inhibitor" CANCER RES. (1998), 58(5), 904-909, XP002177494 abstract page 904, column 2, paragraph 5 page 906, column 2, paragraph 3  WO 01 21192 A (CORINA CORP; CHEEVER MARTIN A (US); GAIGER ALEXANDER (US)) 29 March 2001 (2001-03-29) page 1, paragraph 3; claims page 20, paragraph 3; claims page 20, paragraph 3 — paragraph 4  WO 93 17715 A (IMP CANCER RES TECH; UNIV TEXAS (US)) 16 September 1993 (1993-09-16) claims 1,32,33

Interna. al Application No
PCT/US 00/31424

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT  Citation of document, with indication, where appropriate, of the relevant passages	Dolov
itegory °	Citation of document, with indication, where appropriate, or the relevant passages	Relevant to claim No.
· , X	MANDLER, RAYA ET AL: "Immunoconjugates of geldanamycin and anti-HER2 monoclonal antibodies: antiproliferative activity on human breast carcinoma cell lines"  J. NATL. CANCER INST. (2000), 92(19), 1573-1581,  XP001024069 page 1574, column 2, paragraph 2 -page 1575, column 2, paragraph 4; figure 1	1-66
(	DATABASE CA 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MOKOTOFF, MICHAEL ET AL: "Targeting growth factor receptors with bispecific" molecules" retrieved from STN Database accession no. 124:333195 XP002177495 abstract & CURR. MED. CHEM. (1996), 3(2), 87-100,	
X	DE SANTES, KENNETH ET AL: "Radiolabeled antibody targeting of the HER-2/neu oncoprotein" CANCER RES. (1992), 52(7), 1916-23, XP002177517 cited in the application abstract; figure 4 page 1920, column 2, paragraph 3; figures	1-66

Information on patent family members

Interna al Application No
PCT/US 00/31424

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0100244	A	04-01-2001	AU	5632900 A	31-01-2001
			ΑU	5763200 A	31-01-2001
			WO	0100244 A2	04-01-2001
			WO	0100245 A2	04-01-2001
WO 0121192	Α	29-03-2001	- <b></b>	7710300 A	24-04-2001
			WO	0121192 A2	29-03-2001
WO 9317715	Α	16-09-1993	 AU	3737893 A	05-10-1993
			CA	2131528 A1	16-09-1993
			EP	0627940 A1	14-12-1994
			WO	9317715 A1	16-09-1993
			US	5855866 A	05-01-1999
			US	6261535 B1	17-07-2001
			US	6004554 A	21-12-1999
			US	5965132 A	12-10-1999
			US	5776427 A	07-07-1998
			US	5660827 A	26-08-1997
			US	5863538 A	26-01-1999
			US	6051230 A	18-04-2000
			US	6036955 A	14-03-2000
			US	5877289 A	02-03-1999
			US	6093399 A	25-07-2000
			US	6004555 A	21-12-1999